Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 7/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19036905 | 0.85 | GRM5 (0.43) | CYP3A4CYP2C9CYP2D6CYP2C19ACACB | |
| SCHEMBL23511786 | 0.81 | ALDH1A1 (0.41) | CYP3A4CYP2C9CYP2D6CYP2C19ACACB | |
| SCHEMBL18608233 | 0.75 | KCNH2 (0.51) | CYP3A4CYP2C9CYP2D6CYP2C19ITK | |
| SCHEMBL10488162 | 0.73 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2D6CYP2C19ITK | |
| SCHEMBL29084200 | 0.73 | APP (0.53) | CYP3A4CYP2C9CYP2D6CYP2C19KCNH2 | |
| SCHEMBL12016065 | 0.73 | LMNA (0.46) | CYP3A4CYP2C9CYP2D6CYP2C19GRM5 | |
| SCHEMBL17729351 | 0.73 | APP (0.53) | CYP3A4CYP2C9CYP2D6CYP2C19KCNH2 | |
| SCHEMBL25864597 | 0.73 | CYP3A4 (0.41) | CYP3A4CYP2C9CYP2D6CYP2C19ACACB | |
| SCHEMBL8349426 | 0.72 | CYP2C19 (0.52) | CYP3A4CYP2C9CYP2D6CYP2C19HTR2A | |
| SCHEMBL19629593 | 0.72 | CYP2A6 (0.47) | CYP3A4CYP2C9CYP2D6CYP2C19ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | LYSOSOMAL THERAPEUTICS INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2018-07-05 | — | — | US | disclosed |
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - R&D INVESTMENTS, S.A. (PT) | 2017-11-23 | — | — | US | disclosed |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | BIAL - BIOTECH INVESTMENTS, INC. (PT) | 2017-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334916-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | PARK7, PNP, GAA | CYP3A4 1441/4885CYP2C9 1008/4885CYP2D6 734/4885 |
| US-20170333435-A1 | SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | GAA, GBA1, PARK7 | CYP3A4 1952/4885CYP2C9 1429/4885CYP2D6 1035/4885 |
| US-20180185368-A1 | SUBSTITUTED PYRROLO[1,2-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | TYMP, PARK7, PNP | CYP3A4 2968/4885CYP2C9 2300/4885CYP2D6 1113/4885 |
| US-10570135-B2 | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders | PARK7, PNP, GAA | CYP3A4 1441/4885CYP2C9 1008/4885CYP2D6 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.